Michael J. Fusco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael J. Fusco has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Paul G. Kluetz
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
3 shared publications - Richard Pazdur
Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD
3 shared publications - Bronwyn D. Mixter
Oncology Center of Excellence (OCE), U.S. Food and Drug Administration, Silver Spring, MD
2 shared publications Christine M. Walko
Department of Individualized Cancer Medicine, Moffitt Cancer Center, Tampa, FL, USA
2 shared publicationsEdwin Peguero
Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, USA
2 shared publications- Gulsum E. Pamuk
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
2 shared publications
Latest Publications
- 29 May 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (15) , 3100-3104
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
On November 8, 2023, the FDA approved fruquintinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type and medically appropriate, an anti-EGFR therapy. Approval was based on Study FRESCO-2, a globally conducted, double-blind, placebo-controlled randomized trial. The primary endpoint was overall survival (OS). The key secondary endpoint was progression-free survival. A total of 691 patients were randomly assigned (461 and 230 into the fruquintinib and placebo arms, respectively). Fruquintinib provided a statistically significant improvement in OS with a hazard ratio (HR) of 0.66 [95% confidence interval (CI), 0.55, 0.80; P < 0.001]. The median OS was 7.4 months (95% CI, 6.7, 8.2) in the fruquintinib arm and 4.8 months (95% CI, 4.0, 5.8) for the placebo arm. Adverse events observed were generally consistent with the known safety profile associated with the inhibition of VEGFR. The results of FRESCO-2 were supported by the FRESCO study, a double-blind, single-country, placebo-controlled, randomized trial in patients with refractory mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. In FRESCO, the OS HR was 0.65 (95% CI, 0.51, 0.83; P < 0.001). FDA concluded that the totality of the evidence from FRESCO-2 and FRESCO supported an indication for patients with mCRC with prior treatment with fluoropyrimidine, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type and medically appropriate, an anti-EGFR therapy.
- 29 May 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (15) , 3100-3104
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
On November 8, 2023, the FDA approved fruquintinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type and medically appropriate, an anti-EGFR therapy. Approval was based on Study FRESCO-2, a globally conducted, double-blind, placebo-controlled randomized trial. The primary endpoint was overall survival (OS). The key secondary endpoint was progression-free survival. A total of 691 patients were randomly assigned (461 and 230 into the fruquintinib and placebo arms, respectively). Fruquintinib provided a statistically significant improvement in OS with a hazard ratio (HR) of 0.66 [95% confidence interval (CI), 0.55, 0.80; P < 0.001]. The median OS was 7.4 months (95% CI, 6.7, 8.2) in the fruquintinib arm and 4.8 months (95% CI, 4.0, 5.8) for the placebo arm. Adverse events observed were generally consistent with the known safety profile associated with the inhibition of VEGFR. The results of FRESCO-2 were supported by the FRESCO study, a double-blind, single-country, placebo-controlled, randomized trial in patients with refractory mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. In FRESCO, the OS HR was 0.65 (95% CI, 0.51, 0.83; P < 0.001). FDA concluded that the totality of the evidence from FRESCO-2 and FRESCO supported an indication for patients with mCRC with prior treatment with fluoropyrimidine, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type and medically appropriate, an anti-EGFR therapy.
- 12 December 2023
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (12) , 2515-2524
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development
Summary: Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
- 12 December 2023
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (12) , 2515-2524
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development
Summary: Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.
- 2 December 2022
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 12 (12) , 2739-2746
Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development
Summary: In 2022, cancer drug development continued to progress rapidly despite the lingering COVID-19 pandemic. Highlights of U.S. drug approvals for oncology indications this year include ongoing development in rare diseases and molecular subgroups, improved dosage optimization, and updated data for drugs granted accelerated approval, with confirmatory studies demonstrating verification of clinical benefit in some instances, as well as indication withdrawal when clinical benefit was not verified.
- 2 December 2022
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 12 (12) , 2739-2746
Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug Development
Summary: In 2022, cancer drug development continued to progress rapidly despite the lingering COVID-19 pandemic. Highlights of U.S. drug approvals for oncology indications this year include ongoing development in rare diseases and molecular subgroups, improved dosage optimization, and updated data for drugs granted accelerated approval, with confirmatory studies demonstrating verification of clinical benefit in some instances, as well as indication withdrawal when clinical benefit was not verified.
- Open Access
- 28 January 2022
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 27 (1) , e9-e17
Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary
Cancer of unknown primary (CUP) comprises a heterogeneous collection of malignancies that are typically associated with a poor prognosis and a lack of effective treatment options. We retrospectively evaluated the clinical utility of targeted next-generation sequencing (NGS) among CUP patients to assist with diagnosis and identify opportunities for molecularly guided therapy. Patients with a CUP at Moffitt Cancer Center who underwent NGS between January 1, 2014 and December 31, 2019, were eligible for study inclusion. Next-generation sequencing results were assessed to determine the frequency of clinically actionable molecular alterations, and chart reviews were performed to ascertain the number of patients receiving molecularly guided therapy. Ninety-five CUP patients were identified for analysis. Next-generation sequencing testing identified options for molecularly guided therapy for 55% (n = 52) of patients. Among patients with molecularly guided therapy options, 33% (n = 17) were prescribed a molecularly guided therapy. The median overall survival for those receiving molecularly guided therapy was 23.6 months. Among the evaluable patients, the median duration of treatment for CUP patients (n = 7) receiving molecular-guided therapy as a first-line therapy was 39 weeks. The median duration of treatment for CUP patients (n = 8) treated with molecularly guided therapy in the second- or later-line setting was 13 weeks. Next-generation sequencing results were found to be suggestive of a likely primary tumor type for 15% (n = 14) of patients. Next-generation sequencing results enabled the identification of treatment options in a majority of patients and assisted with the identification of a likely primary tumor type in a clinically meaningful subset of patients.
- 28 January 2022
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 27 (1) , e9-e17
Open AccessEvaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary
Cancer of unknown primary (CUP) comprises a heterogeneous collection of malignancies that are typically associated with a poor prognosis and a lack of effective treatment options. We retrospectively evaluated the clinical utility of targeted next-generation sequencing (NGS) among CUP patients to assist with diagnosis and identify opportunities for molecularly guided therapy. Patients with a CUP at Moffitt Cancer Center who underwent NGS between January 1, 2014 and December 31, 2019, were eligible for study inclusion. Next-generation sequencing results were assessed to determine the frequency of clinically actionable molecular alterations, and chart reviews were performed to ascertain the number of patients receiving molecularly guided therapy. Ninety-five CUP patients were identified for analysis. Next-generation sequencing testing identified options for molecularly guided therapy for 55% (n = 52) of patients. Among patients with molecularly guided therapy options, 33% (n = 17) were prescribed a molecularly guided therapy. The median overall survival for those receiving molecularly guided therapy was 23.6 months. Among the evaluable patients, the median duration of treatment for CUP patients (n = 7) receiving molecular-guided therapy as a first-line therapy was 39 weeks. The median duration of treatment for CUP patients (n = 8) treated with molecularly guided therapy in the second- or later-line setting was 13 weeks. Next-generation sequencing results were found to be suggestive of a likely primary tumor type for 15% (n = 14) of patients. Next-generation sequencing results enabled the identification of treatment options in a majority of patients and assisted with the identification of a likely primary tumor type in a clinically meaningful subset of patients.
- Open Access
- 1 January 2021
- Published by SAGE Publications in Cancer Control
- Vol. 28
Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas
BRAF V600 E mutations have been identified in a subset of patients with primary brain tumors. Combination therapy with BRAF and Mitogen-activated protein kinase (MEK) inhibitors (BRAF/MEKi) targeting sequential steps in the MAPK pathway has replaced BRAFi monotherapy as the standard of care in multiple tumors with BRAF V600 E mutations, and clinical evidence for this strategy continues to grow in primary brain tumors. We describe four patients with BRAF V600 E mutated gliomas, including a 21-year-old woman with a ganglioglioma WHO grade I, a 19-year-old man with a pleomorphic xanthoastrocytoma WHO grade III, and 21-year-old and 33-year-old women with epithelioid GBM WHO grade IV, who achieved durable progression-free survival with combination BRAF/MEKi. Combination of BRAF/MEK inhibition can be a novel, promising approach as targeted therapy in gliomas with BRAF V600 E mutations, especially those that are resistant to standard therapy. Our cases, along with other early reports utilizing dabrafenib/trametinib, highlight the importance of somatic next-generation sequencing, particularly in younger patients. Interim results from clinical trials utilizing dabrafenib/trametinib have been promising thus far, and our case series suggests that durable clinical benefit is possible, even in the setting of glioblastoma, WHO grade IV.
- 1 January 2021
- Published by SAGE Publications in Cancer Control
- Vol. 28
Open AccessDurable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas
BRAF V600 E mutations have been identified in a subset of patients with primary brain tumors. Combination therapy with BRAF and Mitogen-activated protein kinase (MEK) inhibitors (BRAF/MEKi) targeting sequential steps in the MAPK pathway has replaced BRAFi monotherapy as the standard of care in multiple tumors with BRAF V600 E mutations, and clinical evidence for this strategy continues to grow in primary brain tumors. We describe four patients with BRAF V600 E mutated gliomas, including a 21-year-old woman with a ganglioglioma WHO grade I, a 19-year-old man with a pleomorphic xanthoastrocytoma WHO grade III, and 21-year-old and 33-year-old women with epithelioid GBM WHO grade IV, who achieved durable progression-free survival with combination BRAF/MEKi. Combination of BRAF/MEK inhibition can be a novel, promising approach as targeted therapy in gliomas with BRAF V600 E mutations, especially those that are resistant to standard therapy. Our cases, along with other early reports utilizing dabrafenib/trametinib, highlight the importance of somatic next-generation sequencing, particularly in younger patients. Interim results from clinical trials utilizing dabrafenib/trametinib have been promising thus far, and our case series suggests that durable clinical benefit is possible, even in the setting of glioblastoma, WHO grade IV.
- Open Access
- 21 November 2019
- Published by Springer Nature in Journal of Neurology
- Vol. 267 (3) , 783-790
Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma
Introduction: A patient who was initially considered to have a glioblastoma (GBM) had molecular analysis, showing that it was a pleomorphic xanthoastrocytoma (PXA). Up to 78% of PXA tumors have BRAF V600E mutations. Primary brain tumors with BRAF mutations can have a good response to BRAF MEK inhibitors (BRAF MEKi), and there may be a synergistic response when combined with autophagy inhibitors. Presentation of the case: A 20-year-old man found to have a large brain mass with midline shift underwent resection. He was diagnosed with “GBM” and treated with radiation and temozolomide with subsequent disease recurrence. Review of histology showed malignant PXA with BRAF V600E mutation. Treatment with Dabrafenib and Trametinib was started, and tumor size increased in size after 14 months of treatment. Given studies showing that resistance to BRAF inhibition can be overcome by autophagy inhibition, chloroquine was added. Patient has been on “triple” therapy for 15 months and has radiographically Stable Disease. At MCC, 3% of patients with gliomas have BRAF mutations who could potentially benefit from this combination therapy. Conclusion: This is the first report of a PXA patient receiving therapy with BRAF MEKi and an autophagy inhibitor with prolonged stable disease. This patient highlights the importance of a molecular interrogation in gliomas to provide an integrated diagnosis and effective treatment. This may be useful in up to 3% of glioma patients with BRAF mutations. Molecular testing in neuro-oncology is providing new avenues of diagnosis and treatment, and detailed molecular interrogation should be considered routine.
- 21 November 2019
- Published by Springer Nature in Journal of Neurology
- Vol. 267 (3) , 783-790
Open AccessUsing personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma
Introduction: A patient who was initially considered to have a glioblastoma (GBM) had molecular analysis, showing that it was a pleomorphic xanthoastrocytoma (PXA). Up to 78% of PXA tumors have BRAF V600E mutations. Primary brain tumors with BRAF mutations can have a good response to BRAF MEK inhibitors (BRAF MEKi), and there may be a synergistic response when combined with autophagy inhibitors. Presentation of the case: A 20-year-old man found to have a large brain mass with midline shift underwent resection. He was diagnosed with “GBM” and treated with radiation and temozolomide with subsequent disease recurrence. Review of histology showed malignant PXA with BRAF V600E mutation. Treatment with Dabrafenib and Trametinib was started, and tumor size increased in size after 14 months of treatment. Given studies showing that resistance to BRAF inhibition can be overcome by autophagy inhibition, chloroquine was added. Patient has been on “triple” therapy for 15 months and has radiographically Stable Disease. At MCC, 3% of patients with gliomas have BRAF mutations who could potentially benefit from this combination therapy. Conclusion: This is the first report of a PXA patient receiving therapy with BRAF MEKi and an autophagy inhibitor with prolonged stable disease. This patient highlights the importance of a molecular interrogation in gliomas to provide an integrated diagnosis and effective treatment. This may be useful in up to 3% of glioma patients with BRAF mutations. Molecular testing in neuro-oncology is providing new avenues of diagnosis and treatment, and detailed molecular interrogation should be considered routine.
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , 2058
Detection of targetable somatic alterations in glioblastoma (GBM) and clinical impact.
2058 Background: In GBM, molecular markers are utilized to establish an integrated diagnosis as described in the WHO 2016 guidelines and identify patients (pts) with molecular targets amenable to therapeutic intervention. Herein we review our experience at Moffitt Cancer Center. Methods: A retrospective chart review between 4/1/2013 and 11/1/2018 was performed to collect demographic, clinical, disease, treatment and outcome variables on 163 unique pts with GBM whose tumors underwent comprehensive genomic profiling by FoundationOne or CDx testing. Genomic data was analyzed for recurrent alterations and tumor mutational burden (TMB). Results: Median age was 58 years (range 19 to 85). 13% were IDH1 or 2-mutated. Among the 141 IDH-wild type (wt) pts, TERT promoter mutations occurred in 83% and CDKN2A/B co-deletion in 65%. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation was seen in 33%. A median of 5 clinically relevant alterations were identified per tumor sample (range, 2 to 34) and a median of 2 mutations (range, 0 to 6) were found to be actionable after review by our molecular tumor board. The most commonly actionable alterations were found in EGFR, BRAF and genes associated with homologous recombination deficiency (HRD) (see table). Four pts were treated with EGFR-targeted therapy, one pt with an HRD alteration received a PARP inhibitor (progression free survival [PFS] of 34 weeks), and two pts with BRAF V600E received dabrafenib/trametinib combination therapy (treatment ongoing at 14 weeks and 38 months, respectively). Median TMB (n = 118) was 4 (range, 0 to 371 Muts/Mb). One pt who received 44 months of temozolomide exposure had a hypermutated tumor (371 Muts/Mb) and was treated on trial with pembrolizumab, but progressed after 2 months. Conclusions: Though limited in patients with GBM, clinically actionable alterations are found in a small subset and can translate into meaningful clinical benefit. [Table: see text]
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , 2058
Detection of targetable somatic alterations in glioblastoma (GBM) and clinical impact.
2058 Background: In GBM, molecular markers are utilized to establish an integrated diagnosis as described in the WHO 2016 guidelines and identify patients (pts) with molecular targets amenable to therapeutic intervention. Herein we review our experience at Moffitt Cancer Center. Methods: A retrospective chart review between 4/1/2013 and 11/1/2018 was performed to collect demographic, clinical, disease, treatment and outcome variables on 163 unique pts with GBM whose tumors underwent comprehensive genomic profiling by FoundationOne or CDx testing. Genomic data was analyzed for recurrent alterations and tumor mutational burden (TMB). Results: Median age was 58 years (range 19 to 85). 13% were IDH1 or 2-mutated. Among the 141 IDH-wild type (wt) pts, TERT promoter mutations occurred in 83% and CDKN2A/B co-deletion in 65%. O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation was seen in 33%. A median of 5 clinically relevant alterations were identified per tumor sample (range, 2 to 34) and a median of 2 mutations (range, 0 to 6) were found to be actionable after review by our molecular tumor board. The most commonly actionable alterations were found in EGFR, BRAF and genes associated with homologous recombination deficiency (HRD) (see table). Four pts were treated with EGFR-targeted therapy, one pt with an HRD alteration received a PARP inhibitor (progression free survival [PFS] of 34 weeks), and two pts with BRAF V600E received dabrafenib/trametinib combination therapy (treatment ongoing at 14 weeks and 38 months, respectively). Median TMB (n = 118) was 4 (range, 0 to 371 Muts/Mb). One pt who received 44 months of temozolomide exposure had a hypermutated tumor (371 Muts/Mb) and was treated on trial with pembrolizumab, but progressed after 2 months. Conclusions: Though limited in patients with GBM, clinically actionable alterations are found in a small subset and can translate into meaningful clinical benefit. [Table: see text]